TARSUS PHARMACEUTICALS

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

01 авг 2023 22:30:33 Источник Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

31 июл 2023 16:29:44 Источник Nasdaq GlobeNewswire

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

12 июн 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus to Present at the Jefferies Global Healthcare Conference

05 июн 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

09 май 2023 16:05:02 Источник Nasdaq GlobeNewswire

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

08 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

03 май 2023 16:30:00 Источник Nasdaq GlobeNewswire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

24 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

13 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

02 мар 2023 16:30:00 Источник Nasdaq GlobeNewswire

Tarsus Added to NASDAQ Biotechnology Index

16 дек 2022 07:00:00 Источник Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

15 дек 2022 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

09 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

25 окт 2022 08:30:01 Источник Nasdaq GlobeNewswire

Tarsus Announces Transition Plans for Board of Directors

11 окт 2022 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

06 окт 2022 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

29 сен 2022 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings

27 сен 2022 12:00:00 Источник Nasdaq GlobeNewswire

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

07 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

11 авг 2022 16:05:00 Источник Nasdaq GlobeNewswire